多巴丝肼片在中国健康受试者中空腹和餐后条件下的生物等效性研究
李林 , 夏玉明 , 沈陈林 , 夏泉 , 宋帅
中国临床药理学与治疗学 ›› 2026, Vol. 31 ›› Issue (7) : 899 -907.
多巴丝肼片在中国健康受试者中空腹和餐后条件下的生物等效性研究
Bioequivalence study of levodopa and benserazide hydrochloride tablets in healthy Chinese subjects under fasting and fed conditions
目的: 评价空腹和餐后给药条件下,健康受试者口服两种多巴丝肼片的生物等效性。方法: 采用随机、开放、单剂量、两序列、四周期、完全重复交叉试验设计。纳入 64 例健康受试者,空腹和餐后均入组 32 例受试者,各分为两组,每组 16 例。每周期服用受试制剂 1 片或参比制剂 1 片,5 天后交叉给药,清洗期均为 5 d。采用液相色谱串联质谱法测定左旋多巴和三羟基苄肼的血药浓度,使用 WinNonlin 8.1 软件计算其药动学参数,评价两制剂的生物等效性。结果: 空腹给药后,受试制剂和参比制剂的左旋多巴 Cmax 分别为 (4 261.10±1 709.86)和 (4 157.00±1 538.07) ng/mL, AUC0-t 分别为 (7 427.57±1 409.34)和 (7 060.07±1 389.62)h·ng·mL−1、 AUC0-∞分别为 (7 472.97±1 411.51)和 (7 146.98±1 295.45)h· ng·mL−1;三羟基苄肼 Cmax 分别为(27.99±13.38) 和(26.56±14.06)ng/mL、AUC0-t 分别为(17.85± 6.00)和(17.22±5.39)h·ng·mL−1、AUC0-∞分别为 (19.00±6.39)和(18.39±5.85)h·ng·mL−1。餐后 试验中,受试制剂和参比制剂的左旋多巴 Cmax 分 别为(3 338.28±1 493.52)和(3 325.30±1 524.62) ng/mL、 AUC0-t 分别为 (6 744.79±1 325.04)和 (6 615.38±1 364.12)h·ng·mL−1、 AUC0-∞分别为 (6 786.27±1 326.03)和 (6 658.58±1 358.30)h· ng·mL−1;三羟基苄肼 Cmax 分别为(8.35±6.49)和 (8.44±6.44)ng/mL、 AUC0-t 分别为 (6.71±4.14) 和(6.81±3.79)h·ng·mL−1、AUC0-∞分别为(7.14± 4.27)和(7.23±3.98)h·ng·mL−1。空腹和餐后试 验中受试和参比制剂主要药动学参数的几何均值 比 90%CI 均在 80.00%~125.00%。试验期共发生 27 例次(空腹 17 例次,餐后 10 例次)不良事 件,无严重不良事件。结论: 空腹和餐后给药条件 下,受试者口服受试制剂与参比制剂具备生物等 效性,且二者安全性良好。
AIM: To evaluate the bioequivalence of generic and original levodopa-benserazide tablets in healthy Chinese subjects under fasting and fed conditions. METHODS: A randomized, open-label, single-dose, two-sequence, four-period, fully replicated crossover study design was employed. A total of 64 healthy subjects were enrolled, with 32 subjects in the fasting group and 32 in the fed group, each divided into two groups of 16 subjects. Each subject received either one tablet of the test formulation or one tablet of the reference formulation in each period, with a washout period of 5 days between doses. The plasma concentrations of levodopa and tri-hydroxybenzylhydrazine were measured using liquid chromatography-tandem mass spectrometry, and pharmacokinetic parameters were calculated using WinNonlin 8.1 software to assess the bioequivalence of the two formulations. RESULTS: Under fasting conditions, the Cmax of levodopa for the test and reference formulations were (4 261.10±1 709.86) ng/mL and (4 157.00±1 538.07) ng/mL, respectively. The AUC0-t values were (7 427.57±1 409.34) h·ng·mL−1 and (7 060.07±1 389.62) h·ng·mL−1, while AUC0-∞ values were (7 472.97±1 411.51) h·ng·mL−1 and (7 146.98±1 295.45) h·ng·mL−1, respectively. For tri-hydroxybenzylhydrazine, Cmax values were (27.99±13.38) ng/mL and (26.56±14.06) ng/mL; AUC0-t were (17.85±6.00) h·ng·mL−1 and (17.22±5.39) h·ng·mL−1, respectively; and AUC0-∞values were (19.00±6.39) h·ng·mL−1 and (18.39±5.85) h·ng·mL−1, respectively. In the fed trials, the Cmax of levodopa for the test and reference formulations were (3 338.28±1 493.52) ng/mL and (3 325.30±1 524.62) ng/mL, respectively; AUC0-t values were (6 744.79±1 325.04) h·ng·mL−1 and (6 615.38±1 364.12) h·ng·mL−1, respectively; and AUC0-∞ values were (6 786.27±1 326.03) h·ng·mL−1 and (6 658.58±1 358.30) h·ng·mL−1, respectively. The Cmax, AUC0-t, and AUC0-∞ values for trihydroxybenzylhydrazine were (8.35 ± 6.49) and (8.44 ± 6.44) ng/mL, (6.71 ± 4.14) and (6.81 ± 3.79) h·ng·mL−1, and (7.14 ± 4.27) and (7.23 ± 3.98) h·ng·mL−1, respectively.The geometric mean ratios of the primary pharmacokinetic parameters for both formulations under fasting and fed conditions fell within the 90% confidence interval of 80.00%-125.00%. A total of 27 adverse events were reported during the study (17 in the fasting group and 10 in the fed group), with no serious adverse events occurring. CONCLUSION: The test formulation demonstrates bioequivalence to the reference formulation in healthy subjects under both fasting and fed conditions, with a favorable safety profile.
| [1] |
Hauser RA. Levodopa: past, present, and future[J].Eur Neurol, 2009, 62(1): 1-8. |
| [2] |
|
| [3] |
|
| [4] |
|
| [5] |
高变异药物生物等效性研究技术指导原则[EB/OL]. (2018-10-29). https://www.cde.org.cn/zdyz/domesticinfopagezdyzIdCODE=333fd2eac0928e881578082373233f8a. |
| [6] |
|
| [7] |
|
| [8] |
|
| [9] |
|
| [10] |
|
| [11] |
|
| [12] |
|
| [13] |
|
| [14] |
|
| [15] |
Linazasoro G, |
| [16] |
Nagayama H, Hamamoto M, Ueda M, |
| [17] |
|
安徽省转化医学研究院科研项目(2021zhyx-C37)
安徽省高校科研项目(2022AH051154)
安徽省“十三五”临床重点专科建设项目(卫科教秘[2017]529 号)
/
| 〈 |
|
〉 |